Key Takeaways
- Tristel's FY2026 trading update showed Revenue up 10% to £51.1m and adjusted pre-tax profit up 14% to at least £11.5m, ending the year debt-free with cash of £16.0m.
- The company launched 3T Pro, a paid subscription tier of its digital compliance platform, aiming to build recurring software revenue alongside its consumables Business .
- Chris Lee, a 35-year medical technology veteran, took over as chief executive on 1 August 2026, succeeding Matt Sassone.
- FY2025 audited results showed revenue of £46.5m, up 11%, with the adjusted EBITDA Margin improving to 27.8% and the Dividend raised 5% to 14.20p.
- US operations are gaining traction, with Royalty income rising to £108,000 and engagement with roughly 200 US health systems.
Tristel plc (LSE:TSTL), the Cambridgeshire-based maker of chlorine dioxide disinfection products for endoscopes, ultrasound probes and other medical devices, has told shareholders it delivered another year of double-digit growth in the twelve months to 30 June 2026. A trading update released on 22 July showed revenue up 10% to £51.1m and adjusted pre-tax profit rising 14% to at least £11.5m, marginally ahead of market expectations. Five days later the company confirmed the commercial launch of 3T Pro, a paid subscription tier within its digital compliance platform, marking an attempt to build recurring software revenue alongside its consumables business. The news arrives as Tristel changes chief executive, with Chris Lee, a 35-year medical technology veteran, taking charge on 1 August.
What Happened
The trading update confirmed the company ended the year debt-free with cash of £16.0m, up from £12.8m twelve months earlier, and that its adjusted EBITDA margin stayed comfortably above its 25% target.
On 27 July, Tristel announced the commercial launch of 3T Pro, the premium tier of its existing 3T digital platform, which healthcare providers use for staff Training records, device traceability and audit-ready compliance reporting. The company has formalised a three-tier structure: a free tier covering core training and compliance, a mid-tier adding device traceability, and 3T Pro offering advanced customisation, workflow tools and audit reporting for a subscription fee. Group Digital Director Matt Fulford said the launch "reflects the platform's Maturity and healthcare providers' increasing demands" for compliance management tools.
The update also confirmed outgoing chief executive Matt Sassone departed on 30 June, with chief financial officer Anna Wasyl acting as interim CEO before Lee formally takes over. Lee was previously chief executive of Summit Medical Ltd and, before that, Venner Medical International, and spent 18 years at Johnson & Johnson. Chair Bruno Holthof said Lee's "industry experience, especially in the US, makes him the ideal person to lead the business."
Why It Matters
For a company whose growth strategy leans heavily on the US hospital market, appointing a chief executive with deep American healthcare experience is a deliberate signal of intent. Tristel's disinfectant products already carry FDA clearance in several device categories, and the company has been building a network of US health systems and distribution partnerships. A Leadership change layered onto a digital launch designed to build Recurring Revenue suggests the board wants to diversify growth beyond Volume expansion of its wipes and foam disinfection systems. If 3T Pro gains traction, it would give Tristel a subscription revenue stream with different Economics to consumables, potentially supporting margins as it scales internationally.
Latest Financial and Operational Performance
Tristel's (LSE:TSTL) most recently published full audited results, for the year ended 30 June 2025, showed revenue of £46.5m, up 11% on £41.9m, with adjusted pre-tax profit of £10.1m, up 23%. Reported pre-tax profit was £8.4m, up 18%, and the adjusted EBITDA margin improved to 27.8% from 26.0%. The board raised the full-year dividend by 5% to 14.20p, including a final dividend of 8.52p paid in December 2025. Cash and short-term investments stood at £12.8m, with Operating Cash Flow of £10.3m, and the company remained debt-free.
On the US business, the FY2025 results disclosed FDA clearance for Tristel OPH, its ophthalmic device disinfection product, alongside growing royalty income, up to £108,000 from £74,000, and engagement with roughly 200 US health systems. Management described early clinical response to OPH as "highly encouraging" and highlighted a Partnership with Parker Laboratories supporting adoption of its ultrasound disinfection products. The FY2026 trading update showed growth and margin discipline continued, with full audited results due in the autumn.
Key Numbers
- FY2026 revenue: £51.1m, up 10% (FY2025: £46.5m)
- FY2026 adjusted pre-tax profit: expected no less than £11.5m, up 14% (FY2025: £10.1m)
- FY2026 year-end cash: £16.0m, debt-free (FY2025: £12.8m)
- FY2025 adjusted EBITDA margin: 27.8% (FY2024: 26.0%)
- FY2025 full-year dividend: 14.20p per share, up 5% (FY2024: 13.52p)
- FY2025 US royalty income: £108,000 (FY2024: £74,000)
Growth Opportunities
Tristel's stated ambition is double-digit annual revenue growth through to FY2030 while keeping adjusted EBITDA margins at or above 25%. The 3T Pro launch gives it a new lever, converting a compliance and traceability tool providers already use into a paid, higher-margin product line. In consumables, the September 2025 launch of VISICLEAN, a colour-indicator ultrasound probe cleaning solution that turns pink until high-level disinfection is confirmed, has been positioned as a meaningful up-sell opportunity; former CEO Matt Sassone noted cross-selling from the existing DUO ULT product alone could span roughly 14 million cleaning procedures a year. VISICLEAN launched first in the UK, with global rollout dependent on further approvals, while in the US continued FDA clearances and the Parker Laboratories partnership remain central to the growth case.
Risks Investors Should Know
Tristel is navigating two transitions at once: a new chief executive and an unproven digital revenue model. Leadership changes carry integration risk, and it will take further trading periods to establish whether 3T Pro achieves meaningful subscriber adoption rather than remaining a modest contributor. International expansion, particularly in the US, depends on regulatory clearances and health-system procurement cycles outside the company's control. Overseas rollout of products such as VISICLEAN is contingent on further regulatory approval, with no guaranteed timing. As with any small-cap growth story, execution against the FY2030 target must be delivered consistently, not just in one strong year.
What to Watch Next
Investors should watch for Tristel's full audited FY2026 results, expected in autumn 2026, which will confirm the final dividend and add detail beyond the July trading update. Early commentary from Chris Lee on strategic priorities, particularly in the US, will also be watched, along with subscriber uptake for 3T Pro and news on further clearances or rollout for VISICLEAN and Tristel OPH.
Outlook
Tristel enters its new financial year with growth intact, a debt-free Balance Sheet , and two structural changes under way: a chief executive with strong US healthcare credentials and a nascent digital subscription product. Neither has been tested by a full reporting cycle, so the real measure will come with the autumn results and early signs of how quickly 3T Pro and the US strategy translate into sustained Earnings growth.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...